Group 1 - The core viewpoint of the articles is that Capbio (300639) has obtained five invention patents in January 2026, which enhance the company's intellectual property strength and product competitiveness in the fields of bioengineering, microdroplet generation, cell sorting, and nucleic acid testing [1][2] Group 2 - The patents include methods and systems for hybrid analysis, microdroplet generation, live cell sorting, sample preservation, and sample division, which have been authorized in China and Brazil [1] - The patented technologies address industry pain points, such as improving detection accuracy, ensuring consistent droplet volume, increasing sorting accuracy, and effectively preserving viral nucleic acids at room temperature for up to 16 days [1] Group 3 - Capbio aims to become a leading enterprise in nucleic acid molecular diagnostics and is advancing its "Nucleic Acid 99" strategy, which aligns with its development strategy and enhances its core competitiveness [2]

转自：中国证券报·中证网 中证报中证网讯（记者 齐金钊）日前，民爆光电公告，公司拟现金收购厦芝精密51%股权，同时拟通 过发行股份的方式向厦门麦达购买厦芝精密49%股权并募集配套资金。 据悉，厦芝精密战略定位于高端PCB钻针市场，凭借持续的工艺创新与稳定的产品质量，赢得全球知名 PCB制造商认可。合作客户涵盖深南电路、奥特斯（AT&S）、胜宏科技、华通电脑、健鼎科技、沪电 股份、景旺电子、日本名幸电子等国内外龙头企业，客户粘性强。作为业内少数能实现AI服务器板用 钻针、高端载板极小径钻针批量稳定供应的厂商，已跻身核心客户供应链并开展联合开发，深度绑定高 景气赛道需求。 业内人士表示，PCB行业实行严格的"合格供应商认证制度"，需通过管理体系、质量控制、现场审核等 多维度考核，合作一旦建立便形成长期稳定粘性。厦芝精密是国内少数具备50倍径钻针量产能力的企 业，率先切入AI服务器板钻针领域，与胜宏科技、深南电路、景旺电子等头部客户建立稳定合作，先 发优势显著，技术与客户壁垒难以被竞争对手突破。 PCB钻针作为印制电路板制造的核心耗材，其市场需求与电子产业技术迭代深度绑定。随着AI服务器、 5G通讯、汽车电子等高端 ...

中证报中证网讯(记者龚梦泽)日前，北京越野在嘉兴举办相关活动，同步推出BJ40家族三款车型，并启 动相关越野项目及官方俱乐部，开启"中国大环线"，进一步完善其越野产品与服务生态。此次推出的三 款车型涵盖增程、燃油等动力类型，进一步丰富企业产品矩阵。 北京越野本次活动同步启动的越野线路项目，配套建设官方服务与应急保障体系，呼应企业用户共创的 发展方向。北京越野董事长王昊此前在接受中国证券报采访时曾表示，企业焕新核心在于产品创新，将 通过全体系变革，实现从产品供给到用户需求的精准对接，巩固越野赛道核心竞争力。 北汽集团董事长张建勇在近期相关会议中提及，北京越野将持续以创新与用户共创为驱动，依托集团战 略支撑，优化越野产品及服务体系，推动越野品类高质量发展。据悉，北京越野2025年批发与终端销量 双双突破14.1万辆，同比实现增长，核心战略聚焦新能源转型与全细分市场布局，深耕越野领域技术突 破与用户需求挖掘。 ...

转自：中国证券报·中证网 中证报中证网讯（记者 王婧涵）2月2日，记者从国航获悉，2026年春运期间，国航计划执行的客运航 班总量将超过7万班次，较2025年春运增长约10.1%，在册飞机数量同比增加25架，日均航班量约1800 班次。为应对"四流叠加"的出行需求，运力投放进行了针对性调整。 国际方面，国航春运期间运力投入同比增长10.1%，增投覆盖悉尼、奥克兰、新加坡、首尔、曼谷等地 的17条热门航线。 为服务冰雪旅游市场，国航在东北地区运力投入同比增长15%，北京、成都、上海、杭州等地至哈尔滨 的航线已陆续投入宽体机运营，每周新增座位超1.2万个。 在西部地区，国航增班超500班次，覆盖丽江、大理、西双版纳、阿勒泰、喀什等热门旅游目的地。 国航表示，春运期间，国航9架C919国产大飞机将全部投入春运航班运行，继续执飞北京至杭州、成 都、武汉、西安等航线。此外，国航还宣布将部分现有服务进行整合升级，例如将覆盖13条航线的"国 航快线"产品进行标准化。 国内方面，国航重点聚焦京津冀、长三角、粤港澳、成渝四大城市群间的近50条骨干航线，航线范围覆 盖全国，航班保持高位运行。为满足旅客暖冬出行需求，国航在华南及海 ...

Core Viewpoint - The National Healthcare Security Administration (NHSA) has issued a notice outlining nine key tasks for the regulation of the medical insurance fund in 2026, emphasizing the importance of maintaining a high-pressure regulatory environment to ensure the safety of the medical insurance fund [1][2]. Group 1: Regulatory Measures - The notice emphasizes the continuation of special rectification of prominent issues in medical insurance fund management, with local healthcare departments required to ensure accountability at the highest level and implement multiple measures to enhance rectification efforts [1]. - A comprehensive expansion and quality improvement of flying inspections will be promoted, covering all provinces and various stakeholders, including designated medical institutions and insured individuals, across different types of insurance [1]. Group 2: Technological Innovations - The notice highlights the exploration of innovative applications of cutting-edge technologies such as artificial intelligence in regulatory practices, including the development of big data regulatory models to address challenges associated with DRG/DIP payment methods [2]. - The integration of artificial intelligence with imaging recognition is proposed to accurately identify irregularities in implanted medical materials and fraudulent medical practices [2]. Group 3: Systematic Improvements - The notice calls for the continuous improvement of a comprehensive intelligent regulatory system, aiming for over 70% of designated medical institutions to be connected to a pre-reminder system by the end of 2026 [2]. - It also emphasizes the need to establish long-term regulatory mechanisms, including the development of detailed implementation rules for the supervision of medical insurance fund usage and the management of personal accounts in retail pharmacies [2].

中证报中证网讯(记者杨洁)在全球能源博弈加剧与绿色贸易壁垒高筑的复杂形势下，中国如何端稳能源 饭碗，企业如何应对？近日，2026国际能源经济可持续发展大会暨第三届泛能源大数据学术研讨会在清 华大学举办，聚集众多院士专家探讨这一话题。会上发起"泛能源大数据大科学设施计划"全球倡议，同 时宣布启动"中国绿造"雄心领航计划，该计划将以产业实践生态为导向，联动链主企业推动绿色制造规 模化落地。 中国工程院院士、山东省科协主席凌文表示，我国不能脱离应用场景谈能源，要以技术与标准构建产业 的绿色竞争力。 "根据IEA报告，预计2026年全球数据中心用电量将达到900~1100太瓦时，AI正快速成为数据中心用电 主力，现有能源体系面临严峻考验"。中国工程院院士、中国工程院原副院长谢克昌演讲中列出的一组 数据，凸显能源系统变革的紧迫性。他指出，当前正处于国家"十五五"规划启幕与全球2030可持续发展 议程冲刺的历史交汇点，能源安全、新一轮科技革命能源需求、欧盟CBAM碳关税等多重挑战交织，传 统单一学科研究范式已难以应对。 谢克昌院士团队自2013年起探索构建"能源专业知识服务系统"，进而提出"泛能源大数据(EEBD)"理 ...

Core Viewpoint - Shenzhen Beixin Life Technology Co., Ltd. has received approval for its initial public offering and is set to list on the Sci-Tech Innovation Board, focusing on innovative medical devices for precise diagnosis and treatment of cardiovascular diseases [1] Group 1: Company Overview - Beixin Life is a national high-tech enterprise specializing in the research, production, and sales of innovative medical devices for cardiovascular disease diagnosis and treatment [1] - The company is the first in China to have a product combination of intravascular functional FFR and imaging IVUS, establishing a high-performance and high-barrier system for active interventional medical devices [2] Group 2: Product Development and Innovation - As of September 30, 2025, Beixin Life has launched 11 products and has 6 products under research, covering five major categories including IVUS systems and FFR systems [2] - The core product, the IVUS system, is the first domestically developed 60MHz high-definition and high-speed IVUS product approved by the National Medical Products Administration, featuring high definition, speed, and intelligence [2] Group 3: Financial Performance - In the first half of 2025, sales revenue from FFR pressure microcatheters and IVUS catheters accounted for 82.16% of total sales, indicating the continued dominance of core products in the market [3] - Beixin Life achieved a revenue of 259 million yuan and a net profit of 45.51 million yuan in the first half of 2025, marking its first profitable period [3] Group 4: Intellectual Property and Recognition - As of June 30, 2025, Beixin Life holds 185 authorized patents domestically and internationally, including 86 invention patents and 14 PCT international patent applications [4] - The company has been recognized as a "National Specialized and New 'Little Giant' Enterprise" and has received various awards for its core products, highlighting its technological capabilities and market recognition [4] Group 5: Future Outlook - The upcoming IPO is expected to optimize the company's capital structure, reduce debt risk, and enhance its research and development capabilities [6] - Beixin Life aims to continue advancing its product development and expand the application range of existing products, solidifying its comprehensive platform for cardiovascular disease diagnosis and treatment [6]

Core Viewpoint - Zhiyuan Huilian has reported a significant growth in its government business segment, with a year-on-year increase of over 30% in government order amounts for the 2025 fiscal year [1][2] Group 1: Performance Highlights - The company has successfully integrated AI capabilities into core government office scenarios, transitioning from "process-driven" to "intelligent-driven" operations [1] - In 2025, the total contract signing amount for government clients exceeded 5000, with 11 new city-level or above clients signed, indicating a strong penetration in the medium and large government market [1] - The company has achieved operational breakthroughs in highly specialized sectors such as public security, launching over 10 AI intelligent application projects [1] Group 2: AI Integration and Solutions - Zhiyuan Huilian has developed intelligent solutions based on large model capabilities, covering functions such as intelligent writing, law enforcement documentation, policy payment, and intelligent inquiry [1] - The introduction of the "Ask and Act" intelligent assistant and eight core intelligent scenarios for digital agencies has transformed AI from a mere algorithm model into an operational business tool [1] - In Hunan Public Security, the "Xiao Jing" intelligent assistant has tripled material writing efficiency, while the integrated government platform in Luzhou has improved cross-department collaboration efficiency by 173% and overall intelligent office levels by 230% [1] Group 3: Strategic Initiatives - To address the unique attributes of the government market, the company has launched an SM intranet office solution that meets security assessment requirements, ensuring the safety of government data [2] - The establishment of the "AICITY@City Intelligent Body Ecological Alliance" with partners like Huawei and iFLYTEK extends the company's reach into the digital needs of grassroots governments [2] - The company has initiated a research project on "Artificial Intelligence + Digital Agencies" in collaboration with top expert teams to ensure product evolution aligns with policy trends and grassroots realities [2] Group 4: Future Growth Potential - Industry experts indicate that the high growth of Zhiyuan Huilian's government segment in 2025 is attributed to its deep focus on "intelligent touchpoints" within government processes [2] - The optimization of delivery costs is expected to turn the substantial high-quality government orders accumulated in 2025 into a key driver for the company's performance in 2026 [2]

转自：中国证券报·中证网 中证报中证网讯（记者 王婧涵）近日，启明星辰发布2025年业绩预告显示，公司预计实现营业收入23 亿元至24.2亿元。2025年公司净利润亏损，但第四季度业绩已展现出企稳向好的韧性，公司经营性净现 金流约2.9亿元，同比增长约190%，连续三个季度保持净流入态势。 公告显示，利润空间收窄主要源于毛利额的显著下滑。为把握重点行业的安全能力建设机遇，启明星辰 前瞻性地承担了科研类重大项目。因此类项目前期资源投入整体较高，因而对公司整体毛利水平产生阶 段性影响。 报告期内，网络安全市场需求仍待复苏，启明星辰表示，由于部分下游行业客户网络安全支出收紧，公 司整体业务与经营业绩产生阶段性压力。然而随着市场需求逐步筑底，公司第四季度收入降幅已呈现环 比收窄的积极信号。 面对外部挑战，启明星辰表示公司积极优化业务布局，着力培育新兴增长点，稳步推动业务结构调整。 公司在"AI+安全"技术方向，基于"安星人工智能安全运营系统"打造多智能体协同防御体系，实现威胁 全生命周期精准管控；在工业互联网安全方向，打造"京津冀产业协同与工业互联网网络安全平台"，构 建"六位一体"工业安全防护体系；在个人隐私保护方 ...

此外，公司于1月30日召开2026年第一次临时股东会，选举产生了5名非独立董事和3名独立董事，并于 当天召开董事会，完成了新一届董事长、专门委员会及高级管理人员的选举及聘任。本次换届后，荃银 高科董事长更换为现任中种集团执行董事姜业奎，新任总经理宋维波曾任中种集团总经理等职，新任财 务总监刘俊茹曾任中种集团财务负责人。 中证报中证网讯(记者乔翔)荃银高科（300087）日前发布2025年业绩预告，预计2025年业绩出现亏损。 对此，公司表示，2025年种子行业仍然面临着高库存、同质化严重的激烈市场竞争环境，同时受到自然 灾害的影响，导致公司种子销售价格下行、毛利率下降。公司根据《企业会计准则》以及会计政策的相 关要求，结合市场及行业情况并基于谨慎性原则对应收款项、存货以及商誉等计提了充分的减值准备。 ...